DGX QUEST DIAGNOSTICS INC
Services-Medical Laboratories · NYSE · SEC CIK 1022079 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.1%
TTM net income YoY16.5%
TTM EPS YoY17.8%
Revenue 3-yr CAGR8.4%
Net income 3-yr CAGR14.0%
Margins
Gross margin33.1%
Operating margin14.6%
Net margin9.5%
FCF margin11.6%
EBITDA margin19.5%
Returns
ROE15.2%
ROA6.8%
ROIC (approx.)10.7%
Asset turnover0.71x
Leverage & solvency
Liabilities / assets53.4%
Debt / equity0.73x
Current ratio1.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.73x
Accruals ratio-4.9%
Payout ratio32.7%
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.10B | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B |
| Cost of revenue | $2.06B | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B |
| Gross profit | $1.04B | $1.03B | $942.00M | $910.00M | $949.00M | $943.00M | $863.00M | $858.00M |
| SG&A expense | $523.00M | $529.00M | $504.00M | $504.00M | $501.00M | $486.00M | $476.00M | $466.00M |
| Operating income | $479.00M | $459.00M | $399.00M | $386.00M | $386.00M | $438.00M | $346.00M | $361.00M |
| Pretax income | $416.00M | $412.00M | $334.00M | $330.00M | $328.00M | $384.00M | $276.00M | $299.00M |
| Income tax | $99.00M | $88.00M | $74.00M | $81.00M | $77.00M | $97.00M | $59.00M | $68.00M |
| Net income | $312.00M | $320.00M | $252.00M | $245.00M | $245.00M | $282.00M | $220.00M | $222.00M |
| EBITDA | $626.00M | $605.00M | $546.00M | $531.00M | $528.00M | $581.00M | $486.00M | $496.00M |
| EPS (basic) | 2.82 | 2.88 | 2.27 | — | 2.18 | 2.51 | 1.97 | — |
| EPS (diluted) | 2.78 | 2.84 | 2.24 | — | 2.16 | 2.47 | 1.94 | — |
| Dividends declared per share | 0.86 | 0.86 | 0.86 | 0.80 | 0.80 | 0.80 | 0.80 | 0.75 |
| Weighted avg. shares (diluted) | 112.00M | 112.00M | 112.00M | — | 113.00M | 113.00M | 113.00M | — |
| Banking | ||||||||
| Net interest income | -$61.00M | -$63.00M | -$63.00M | -$64.00M | -$66.00M | -$67.00M | -$67.00M | -$65.00M |
| Balance sheet | ||||||||
| Cash & equivalents | $797.00M | $626.00M | $393.00M | $420.00M | $432.00M | $319.00M | $188.00M | $549.00M |
| Receivables | $1.71B | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B |
| Inventory | $218.00M | $233.00M | $225.00M | $189.00M | $186.00M | $187.00M | $189.00M | $188.00M |
| Current assets | $3.12B | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B |
| PP&E, net | $2.27B | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B |
| Goodwill | $9.11B | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B |
| Intangibles | $1.63B | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B |
| Total assets | $17.22B | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B |
| Current liabilities | $1.83B | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B |
| Short-term debt | $10.00M | $10.00M | $503.00M | $504.00M | $504.00M | $504.00M | $1.00M | $602.00M |
| Long-term debt | $5.54B | $5.63B | $5.16B | $5.17B | $5.17B | $5.17B | $5.86B | $5.62B |
| Total debt | $5.55B | $5.64B | $5.66B | $5.67B | $5.67B | $5.67B | $5.86B | $6.22B |
| Total liabilities | $9.19B | $9.04B | $8.93B | $8.94B | $8.82B | $8.62B | $8.75B | $9.26B |
| Shareholders' equity | $7.63B | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B |
| Net debt | $4.75B | $5.02B | $5.26B | $5.25B | $5.24B | $5.35B | $5.67B | $5.67B |
| Cash flow statement | ||||||||
| Operating cash flow | $611.00M | $597.00M | $278.00M | $465.00M | $563.00M | $544.00M | $314.00M | $464.00M |
| Capital expenditure | $166.00M | $138.00M | $114.00M | $158.00M | $144.00M | $108.00M | $117.00M | $123.00M |
| Free cash flow | $445.00M | $459.00M | $164.00M | $307.00M | $419.00M | $436.00M | $197.00M | $341.00M |
| Investing cash flow | -$169.00M | -$134.00M | -$152.00M | -$191.00M | -$201.00M | -$124.00M | -$115.00M | -$502.00M |
| Financing cash flow | -$271.00M | -$229.00M | -$152.00M | -$287.00M | -$247.00M | -$293.00M | -$561.00M | -$170.00M |
| Depreciation & amortization | $147.00M | $146.00M | $147.00M | $145.00M | $142.00M | $143.00M | $140.00M | $135.00M |
| Stock-based compensation | $20.00M | $23.00M | $20.00M | $25.00M | $20.00M | $21.00M | $22.00M | $27.00M |
| Dividends paid | $95.00M | $96.00M | $88.00M | $90.00M | $89.00M | $90.00M | $84.00M | $84.00M |
| Share buybacks | $150.00M | — | — | $300.00M | $150.00M | — | — | $151.00M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.